Abstract 5779: CDK4/6 inhibitors and anaplastic thyroid cancer: An investigation into the retinoblastoma cancer pathway and potential therapeutic targets

Introduction/Background: Recently, Cyclin-dependent kinase (CDK) 4/6 inhibitors have been shown to increase progression-free survival in estrogen receptor-positive, stage IV breast cancer patients. We aim to assess whether Palbociclib, a selective CDK4/6 inhibitor, prevents tumor cell growth in vitr...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2018-07, Vol.78 (13_Supplement), p.5779-5779
Main Authors: Wong, Kristen A., Cristofano, Antonio Di
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction/Background: Recently, Cyclin-dependent kinase (CDK) 4/6 inhibitors have been shown to increase progression-free survival in estrogen receptor-positive, stage IV breast cancer patients. We aim to assess whether Palbociclib, a selective CDK4/6 inhibitor, prevents tumor cell growth in vitro and in vivo in anaplastic thyroid cancer (ATC). ATC carries an automatic stage IV classification and a 6-month survival prognosis; there has been very little advancement in chemotherapeutic options, making it a good disease target for this new class of drug. Retinoblastoma (Rb) is a tumor suppressor protein that is rarely mutated in ATC (
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2018-5779